For patients with T2D uncontrolled on dual therapy with metformin + DPP4i or metformin + SGLT2i 1
NOW PBS
LISTED 3
For patients with T2D uncontrolled on dual therapy with metformin + DPP4i or metformin + SGLT2i 1
JARDIANCE ®( empagliflozin) and TRAJENTA ®( linagliptin) now combined in a once daily tablet 1, 2
For the battle against type 2 diabetes.
PBS Information: GLYXAMBI ®: Authority Required( STREAMLINED). Type 2 Diabetes. Code 7524- Triple therapy, initial treatment( with metformin). Code 7556- Triple therapy, continuing treatment( with metformin). Refer to PBS Schedule for full Authority Required Information.
BEFORE PRESCRIBING, PLEASE REVIEW THE FULL PRODUCT INFORMATION WHICH IS AVAILABLE ON REQUEST FROM BOEHRINGER INGELHEIM OR FROM WWW. BOEHRINGER-INGELHEIM. COM. AU / PI
GLYXAMBI ®( empagliflozin / linagliptin) 10 / 5 mg, 25 / 5 mg film-coated tablets. INDICATIONS: As an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. CONTRAINDICATIONS: Hypersensitivity to empagliflozin or linagliptin or any of the excipients; Patients with eGFR persistently < 45 mL / min / 1.73m 2 or CrCl persistently < 45 mL / min( CKD Stage 3B). PRECAUTIONS: Patients with type 1 diabetes; diabetic ketoacidosis; risk of hypoglycaemia when used in combination with sulfonylureas( SU) and / or insulin; discontinue if pancreatitis is suspected; discontinue when eGFR is persistently below 45mL / min / 1.73m 2 or CrCl < 45mL / min; monitoring of renal function is recommended; patients for whom a drop in BP could pose a risk( e. g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); consider discontinuation in patients with recurrent urinary tract infections( UTIs); discontinue if bullous pemphigoid is suspected; pregnancy; lactation; children(< 18 years). INTERACTIONS: Insulin and SU; diuretics; strong P-gp or CYP3A4 inducers. Others, see full PI. ADVERSE REACTIONS: Common: vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTI; nasopharyngitis; hypoglycaemia( combination with SU or insulin); increased urination; cough; rash; pruritus; lipase increased; serum lipids increased. Others, see full PI. DOSAGE AND ADMINISTRATION: Recommended starting dose is 10mg / 5mg once daily taken with or without food. Patients tolerating 10mg / 5mg once daily and requiring additional glycaemic control, increase dose to 25 mg / 5mg once daily. Patients already on empagliflozin, the dose of GLYXAMBI should provide the dose of empagliflozin similar to the dose already taken. No dose adjustment is recommended: based on age; patients with eGFR ≥45mL / min / 1.73m 2; patients with hepatic impairment. Initiation of GLYXAMBI is not recommended in patients aged ≥75 years. When used in combination with a SU or with insulin, a lower dose of the SU or insulin may be considered to reduce the risk of hypoglycaemia. Boehringer Ingelheim Pty Limited. ABN 52 000 452 308. 78 Waterloo Road North Ryde NSW 2113. January 2018.
References: 1. GLYXAMBI ® Approved Product Information. 2. DeFronzo RA et al. Diabetes Care 2015; 38:384 – 93. 3. Pharmaceutical Benefits Scheme. Available at: www. pbs. gov. au. Accessed April 2018.
Boehringer Ingelheim Pty Limited, ABN 52 000 452 308 78 Waterloo Road, North Ryde, NSW 2113 Australia. Copyright © 2018 BOEH0896RR _ AD _ FP. AU / DIA / 00145b. Prepared April 2018.
Eli Lilly Australia Pty Limited, ABN 39 000 233 992
112 Wharf Road, West Ryde, NSW 2114 Australia Copyright © 2018